mupirocin


Also found in: Dictionary, Wikipedia.
Related to mupirocin: Bactroban

mupirocin

 [mu-pir´o-sin]
an antibacterial derived from Pseudomonas fluorescens, effective against staphylococci and non-enteric streptococci; used in the treatment of impetigo and, as the calcium salt, in the treatment of nasal colonization by Staphylococcus aureus.

mupirocin (pseudomonic acid, pseudomonic acid A)

Bactroban, Bactroban Nasal 2%, Taro-Mupirocin (CA)

Pharmacologic class: Dermatologic agent

Therapeutic class: Anti-infective, topical

Pregnancy risk category B

Action

Inhibits bacterial protein and RNA synthesis by reversibly and specifically binding to bacterial isoleucyl-transfer RNA synthetase. Bactericidal.

Availability

Intranasal ointment: 2.15%

Topical cream: 2%

Topical ointment: 2%

Indications and dosages

Impetigo

Adults and children ages 2 months to 16 years: Apply a small amount of ointment topically t.i.d. for 3 to 5 days. Reevaluate if no response.

Infected traumatic skin lesions

Adults and children ages 3 months to 16 years: Apply a small amount of cream topically t.i.d. for 10 days.

Nasal colonization of methicillin-resistant Streptococcus aureus

Adults and children ages 12 and older: Apply intranasal ointment (half of single-use tube to each nostril) topically to anterior nares b.i.d. for 5 days.

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:

• moderate or severe renal impairment (with large doses)

• breastfeeding patients

• children younger than age 12 (intranasal ointment), younger than age 3 months (cream), or younger than age 2 months (ointment).

Administration

• After intranasal application, press nares together repeatedly to distribute drug.

• Avoid contact with eyes.

• Discontinue use if sensitization or severe local irritation occurs.

• If desired, cover affected area with gauze dressing after applying cream or ointment.

• Don't use intranasal form with any other nasal spray.

• Don't use Bactroban ointment on mucosal surfaces. Use Bactroban Nasal (mupirocin calcium ointment) intranasally.

• Know that although mupirocin isn't absorbed systemically, polyethylene glycol (its water-miscible ointment base) may be absorbed from open wounds and damaged skin and may be excreted by the kidneys.

Adverse reactions

CNS: headache (with intranasal use)

EENT: rhinitis, nasal stinging or burning, pharyngitis (all with intranasal use)

GI: mouth and lip sores

Skin: pruritus (with intranasal use); dry skin, rash, redness, stinging or pain, secondary wound infection

Other: taste disorders (with intranasal use)

Interactions

None significant

Patient monitoring

• Monitor for drug efficacy.

Patient teaching

• Instruct patient to wash affected area with soap and water and dry it thoroughly, then apply small amount of drug to area and rub in gently. If desired, tell him to apply gauze dressing.

• Advise patient to complete entire course of therapy, even if symptoms disappear. Tell him to try not to miss doses.

• If patient misses a dose, tell him to apply dose as soon as he remembers. However, if it's almost time for next dose, advise him to skip missed dose and resume regular dosing schedule.

• Advise patient to contact prescriber if skin infection doesn't improve within 3 to 5 days or if it worsens.

• Caution patient not to apply drug to eye or mucous membranes (except nasal form for intranasal use).

• As appropriate, review all other significant adverse reactions.

mupirocin

Dermatology A topical bactericide that inhibits bacterial protein synthesis. See Methicillin-resistant Staphylococcus aureus.

mupirocin

A broad-spectrum antibiotic used externally on the skin and as a nasal ointment to treat carriers of staphylococci. Brand names are Bactroban and Bactroban nasal.
References in periodicals archive ?
Current treatments include a new topical antibiotic, ozenoxacin (Xepi), retapamulin (Altabax), and the old topical treatments such as mupirocin and fusidic acid (not available in the United States), which are still widely used as first-line therapies.
The minimum inhibitory concentration (MIC) for vancomycin and mupirocin were determined by the broth microdilution test as recommended by CLSI.
The introduction in the mid-1980s of mupirocin calcium ointment led to its widespread use as the decolonization agent of choice for preventing S.
This treatment was as effective as nasal mupirocin. However, mupirocin is not available in China at this time and it is significantly more expensive.
Empiric therapy like anti-MRSA antibiotics should be in consideration.[4] There were no isolates resistant to linezolid, tigecycline, fusidic acid, mupirocin, and vancomycin.
The main antimicrobial used for nasal staphylococcal eradication is mupirocin. Mupirocin, an antibiotic based on a chemical produced by the bacteria Pseudomonas fluorescens, has been used for this purpose since the 1980s when it was shown to be effective at eradicating staphylococcus aureus bacteria.
(7) Minimum inhibitory concentration (MIC) to mupirocin was determined by Etest[R] (AB-Biodisk, Solna, Sweden).
Test group--Topical calcium mupirocin 2% (GlaxoSmithKline Pharmaceuticals, Mumbai)
Mupirocin Calcium is used for the topical treatment of secondary infected traumatic lesions such as small lacerations, sutured wounds or abrasions.
According to drug sensitivity patterns, vancomycin was found sensitive in 100%, linezolid 98.9%, mupirocin 96.8%, rifampicin 95.7%, chloramphenicol 94.7%, clindamycin 86.2%, amikacin 84%, moxifloxacin 83%, fusidic acid 79.8%, gentamicin 76.6%, oxacillin 69.1%, ciprofloxacin 68.1%, amoxicillin-clavulanic acid 62.8%, erythromycin 60.6% and trimethoprim- sulphamethaxazole 57.4% of cases.
A / ALTHOUGH EVIDENCE IS LACKINGING to support a single best treatment for impetigo, topical mupirocin, fusidic acid, gentamicin, and retapamulin are all at least 20% more likely than placebo to produce cure or improvement (strength of recommendation [SOR]: A, meta-analysis of randomized controlled trials [RCTs] and a single RCT of retapamulin).
A randomized controlled trial of topical exit site mupirocin application in patients with tunneled cuffed haemodialysis catheters.